AGTC Licenses Promoter Technology to SparingVision SAS (AGTC News)

AGTC Licenses Promoter Technology to SparingVision SAS

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced a licensing agreement that provides its proprietary cone-specific promoter technology to SparingVision SAS, a genomic medicine company developing vision-saving treatments for ocular diseases.

AGTC’s proprietary PR1.7 cone-specific promoter helps drive increased gene expression in cone photoreceptors only, thereby allowing enhanced targeting of gene therapies for indications in which the gene defect is cone-specific and limiting expression of the gene in other cells that could be undesirable.

Learn more about AGTC Licenses Promoter Technology to SparingVision SAS.
X